MOLECULAR PARTNERS AG
MOLNNasdaq
$3.90
↓ -4.9%Jul 17 close · end-of-day
Price
1Y↑ +6.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Molecular Partners AG focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema. MP0420 is a multi-specific DARPin therapy candidate for the SARS-CoV-2 virus. The company also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia.
- CEO
- Patrick Amstutz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Website
- molecularpartners.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.